A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis

Last updated: May 15, 2008
Sponsor: Pfizer
Overall Status: Completed

Phase

3

Condition

Respiratory Syncytial Virus (Rsv) Infection

Bronchitis (Pediatric)

Throat And Tonsil Infections

Treatment

N/A

Clinical Study ID

NCT00393835
A0661176
  • Ages 16-80
  • All Genders

Study Summary

To evaluate the clinical efficacy and safety in patients with Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis receiving a dose of 2 g of azithromycin in the SR formulation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients who were diagnosed Laryngopharyngitis or Tonsillitis or Acute BacterialRhinosinusitis

Exclusion

Exclusion Criteria:

  • Severe underlying disease; patients in which drug clinical evaluation is difficultbecause of confounding diseases.

Study Design

Total Participants: 99
Study Start date:
November 01, 2006
Estimated Completion Date:
May 31, 2007

Connect with a study center

  • Pfizer Investigational Site

    Gobo, Wakayama 644-8655
    Japan

    Site Not Available

  • Pfizer Investigational Site

    Hashimoto, Wakayama 648-0053
    Japan

    Site Not Available

  • Pfizer Investigational Site

    Shinjo-cho, Tanabe, Wakayama 646-8588
    Japan

    Site Not Available

  • Pfizer Investigational Site

    Wakayama, 640-8435
    Japan

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.